Capital Fund Management S.A. Sells 79,924 Shares of Neurocrine Biosciences, Inc. $NBIX

Capital Fund Management S.A. lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 39.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 123,704 shares of the company’s stock after selling 79,924 shares during the quarter. Capital Fund Management S.A.’s holdings in Neurocrine Biosciences were worth $17,366,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in NBIX. Arrowstreet Capital Limited Partnership grew its position in shares of Neurocrine Biosciences by 87.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 125,162 shares of the company’s stock worth $15,732,000 after buying an additional 58,562 shares during the period. Saturn V Capital Management LP acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $7,313,000. Rhenman & Partners Asset Management AB raised its position in shares of Neurocrine Biosciences by 66.1% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 149,217 shares of the company’s stock valued at $18,755,000 after acquiring an additional 59,400 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in Neurocrine Biosciences by 86.7% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 28,185 shares of the company’s stock worth $3,957,000 after acquiring an additional 13,087 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Neurocrine Biosciences by 113.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 40,859 shares of the company’s stock worth $5,598,000 after acquiring an additional 21,752 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on NBIX shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $175.00 target price (up from $173.00) on shares of Neurocrine Biosciences in a research note on Thursday, January 8th. Zacks Research cut shares of Neurocrine Biosciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, February 17th. Royal Bank Of Canada decreased their price target on shares of Neurocrine Biosciences from $180.00 to $177.00 and set an “outperform” rating for the company in a report on Thursday, February 12th. Stifel Nicolaus raised their price objective on Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, JPMorgan Chase & Co. reduced their target price on Neurocrine Biosciences from $177.00 to $176.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $175.05.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $129.54 on Thursday. The firm has a market cap of $13.00 billion, a P/E ratio of 27.80, a PEG ratio of 0.68 and a beta of 0.32. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $160.18. The firm’s 50 day moving average price is $133.57 and its two-hundred day moving average price is $140.36.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The company had revenue of $805.50 million for the quarter, compared to the consensus estimate of $804.21 million. During the same period in the prior year, the company earned $1.69 EPS. The firm’s revenue was up 28.3% on a year-over-year basis. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Leslie V. Norwalk sold 5,000 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $152.23, for a total transaction of $761,150.00. Following the completion of the transaction, the director owned 7,429 shares in the company, valued at approximately $1,130,916.67. This represents a 40.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kyle Gano sold 36,400 shares of Neurocrine Biosciences stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at $18,632,008.90. This represents a 20.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 42,590 shares of company stock valued at $5,775,987. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.